# US 2022/0017964 A1 · Cornulin (CRNN) Variants And Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0017964 A1
- Document ID: US20220017964A1
- Status: Published application
- Kind: A1
- Application number: 17/378,900
- Filed: 2021-07-19
- Published: 2022-01-20
- Earliest claimed: 2017-10-16
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Claudia Gonzaga-Jauregui; Kavita Praveen
- Web page: https://patentgrep.com/patent/US20220017964A1

## CPC

- C07K 14/435: from animals; from humans
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/156: Polymorphic or mutational markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The disclosure provides nucleic acid molecules, including cDNA, comprising an alteration that encodes a loss-of-function cornulin (CRNN) protein. The disclosure also provides isolated and recombinant human loss-of-function cornulin protein variants that comprise a truncation at a position corresponding to position 79. The truncation, and the nucleic acid molecules encoding this change, associate with skin disorders such as, for example, psoriasis, eczema, or atopic dermatitis. The disclosure also provides methods for determining whether a subject has or has a risk of developing a skin disorder, based on the identification of such alterations in the nucleic acid molecules encoding CRNN. Subjects at risk for or who have a skin disorder may be treated with an agent effective to treat the skin disorder.

## Claims

### Claim at position 1

1-14. (canceled)

### Claim 15

An alteration-specific probe or primer comprising a nucleic acid sequence which is complementary to a nucleic acid sequence of a nucleic acid molecule encoding a cornulin protein truncated at a position corresponding to position 79 according to SEQ ID NO:8, wherein the alteration-specific probe or primer comprises a nucleic acid sequence which is complementary to a portion of the nucleic acid molecule encompassing the codon which encodes a cysteine at the position corresponding to the position 69 according to SEQ ID NO:8.

### Claim at position 3

16-20. (canceled)

### Claim 21

A method of treating a subject with a therapeutic agent that treats or inhibits a skin disorder, wherein the subject has a skin disorder or is at risk of developing a skin disorder, the method comprising:
determining whether the subject has a nucleic acid molecule encoding a loss-of-function cornulin protein by:
obtaining or having obtained a biological sample from the subject; and
performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the nucleic acid molecule encoding the loss-of-function cornulin protein; and
administering or continuing to administer to the subject having a nucleic acid molecule encoding a loss-of-function cornulin protein the therapeutic agent that treats or inhibits the skin disorder;
wherein the presence of a genotype having a nucleic acid molecule encoding a loss-of-function cornulin protein indicates the subject has an increased risk of developing the skin disorder.

### Claim 22 (depends on 21)

The method according to claim 21, wherein the skin disorder is psoriasis, eczema, or atopic dermatitis.

### Claim 23 (depends on 21)

The method according to claim 21, wherein the loss-of-function cornulin protein is a truncated cornulin protein.

### Claim 24 (depends on 23)

The method according to claim 23, wherein the loss-of-function cornulin protein comprises a cysteine at the position corresponding to position 69 according to SEQ ID NO:8.

### Claim 25 (depends on 23)

The method according to claim 23, wherein the loss-of-function cornulin protein comprises a cysteine at the position corresponding to position 69 according to SEQ ID NO:8, and is truncated at a position corresponding to position 79 according to SEQ ID NO:8.

### Claim 26 (depends on 25)

The method according to claim 25, wherein the truncated cornulin protein comprises a different amino acid compared to the wild type cornulin protein at any one of the positions corresponding to positions 69 to 76, 78, and 79 according to SEQ ID NO:8.

### Claim 27 (depends on 25)

The method according to claim 25, wherein the truncated cornulin protein comprises the amino acid sequence of SEQ ID NO:10 at the positions corresponding to positions 69 to 79 according to SEQ ID NO:8.

### Claim 28 (depends on 21)

The method according to claim 21, wherein the loss-of-function cornulin protein comprises SEQ ID NO:8.

### Claim 29 (depends on 21)

The method according to claim 21, wherein the determining step comprises sequencing at least a portion of the nucleic acid molecule that encodes the loss-of-function cornulin protein, wherein the sequenced nucleic acid molecule encodes a cornulin protein truncated at a position corresponding to position 79 according to SEQ ID NO:8.

### Claim 30 (depends on 29)

The method according to claim 29, wherein the portion of the nucleic acid molecule sequenced comprises a plurality of positions encompassing the codon encoding the position corresponding to the position 69 according to SEQ ID NO:8.

### Claim 31 (depends on 29)

The method according to claim 29, wherein the determining step comprises sequencing the entire nucleic acid molecule encoding the loss-of-function cornulin protein.

### Claim 32 (depends on 21)

The method according to claim 21, wherein the determining step comprises:
amplifying at least a portion of the nucleic acid molecule that encodes a cornulin protein, wherein the amplified nucleic acid molecule encompasses the codon encoding the amino acid at the position corresponding to position 69 according to SEQ ID NO:8;
labeling the amplified nucleic acid molecule with a detectable label;
contacting the labeled nucleic acid molecule with a support comprising a probe, wherein the probe comprises a nucleic acid sequence which specifically hybridizes under stringent conditions to a nucleic acid sequence encompassing the codon encoding a cysteine at the position corresponding to position 69 according to SEQ ID NO:8; and
detecting the detectable label.

### Claim 33 (depends on 21)

The method according to claim 21, wherein the determining step comprises:
contacting a nucleic acid molecule that encodes a cornulin protein with a probe comprising a detectable label, wherein the probe comprises a nucleic acid sequence which specifically hybridizes under stringent conditions to a nucleic acid sequence encompassing the codon encoding cysteine at the position corresponding to position 69 according to SEQ ID NO:8; and
detecting the detectable label.

### Claim 34 (depends on 21)

The method according to claim 21, wherein the nucleic acid molecule encoding the loss-of-function cornulin protein is genomic DNA.

### Claim 35 (depends on 34)

The method according to claim 34, wherein the genomic DNA comprises SEQ ID NO:2.

### Claim 36 (depends on 21)

The method according to claim 21, wherein the nucleic acid molecule encoding the loss-of-function cornulin protein is mRNA.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the mRNA comprises SEQ ID NO:4.

### Claim 38 (depends on 21)

The method according to claim 21, wherein the nucleic acid molecule encoding the loss-of-function cornulin protein is cDNA.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the cDNA comprises SEQ ID NO:6.

### Claim 40 (depends on 21)

The method according to claim 21, wherein the therapeutic agent comprises a vitamin.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the vitamin is Vitamin A or Vitamin D.

### Claim 42 (depends on 21)

The method according to claim 21, wherein the therapeutic agent is salicylic acid, eicosapentaenoic acid (EPA), psoralen, cyclosporine, methotrexate, or etanercept.

### Claim 43 (depends on 21)

The method according to claim 21, wherein the therapeutic agent is a corticosteroid.

### Claim 44 (depends on 21)

The method according to claim 21, wherein the therapeutic agent is an antibody.

### Claim 45 (depends on 44)

The method according to claim 44, wherein the antibody is adalimumab, brodalumab, ixekizumab, secukinumab, or ustekinumab.
